EXAI News and Press, Exscientia Limited From 04/19/23

- Includes recent advancements from precision designed compounds - - Functional personalised medicine platform unveiling unique adenosine biomarker to enrich for patients more likely to respond to treatment - Exscientia plc (Nasdaq: EXAI) today announced four pre...

2023-03-23 10:57:47 ET Exscientia press release ( NASDAQ: EXAI ): Q4 GAAP EPS of -$0.38. Revenue of $8.2M (+64.0% Y/Y). For further details see: Exscientia GAAP EPS of -$0.38, revenue of $8.2M

2023-03-23 10:45:04 ET Exscientia plc (EXAI) Q4 2022 Earnings Conference Call March 23, 2023, 08:30 AM ET Company Participants Sara Sherman - VP-IR Andrew Hopkins - CEO Ben Taylor - CFO and Chief Strategy Officer Dave Hallett - Chief Scientific Officer Mi...

Exscientia plc (Nasdaq: EXAI) Recent developments in the Company’s pipeline, collaborations, and operations as well as financial results for the fourth quarter and full year 2022 are summarised below. Exscientia will host a conference call today, March 23, at 12:30 p.m. GMT / 8:30 a....

Company to host conference call and webcast on March 23, 2023 at 12:30 p.m. GMT / 8:30 a.m. EDT Exscientia plc (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended December 31, 2022 on Thursday, March 23, 2023 before the open of U.S. markets. The Compa...

2023-03-15 13:53:58 ET The following slide deck was published by Exscientia plc in conjunction with this event. For further details see: Exscientia (EXAI) Investor Presentation _-Slideshow

– Abstracts highlight pipeline programmes in precision oncology, including novel LSD1 inhibitor – – Further detail on A 2A programme, including novel biomarker for patient selection to be presented – Exscientia plc (Nasdaq: EXAI) today announc...

— Precision designed LSD1 and MALT1 inhibitors currently progressing through IND-enabling studies — — Both m olecules demonstrate Exscientia’s ability to overcome critical design challenges and identify high quality drug candidates with pote...

— Partnership will further validate Exscientia’s functional drug testing platform to predict response in haematological cancers — Exscientia plc (Nasdaq: EXAI) today announced a new collaboration with Charité – Universitätsmedizin Berlin (Ch...

Summary AI has begun to make headways in the field of drug discovery and development. Exscientia offers investors direct exposure to this wave of innovation. The company has attracted risk capital to unlock for sophisticated investors already. Net-net, rate buy. Invest...